ABOUT THIS EPISODE
Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape.
Click here to claim your credit for this podcast:
Click here to claim your credit for this podcast:
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Oncology Data Advisor.
OTHER EPISODES IN THIS PODCAST
What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies?
In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO t…
Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient
The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the mo…
Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging
As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing pati…
View the full article at: https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon
Tumor boards play a pivotal role in oncology care. For clinicians, they represent the ideal environment: multiple specialists, shared context, and time to debate the gray areas that guidelines can’…
Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?
In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred H…
Disclaimer: The podcast and artwork embedded on this page are from i3 Health, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
